Literature DB >> 33296008

Antenatally diagnosed kidney tumor: Answers.

Wiebke Solass1, Hyunkyu Shin1, Cristian Urla2, Andreas Schmidt3.   

Abstract

Entities:  

Keywords:  Congenital mesoblastic nephroma; Nephrectomy; Pediatric neoplasm; Prenatal diagnosis; Renal tumor

Year:  2020        PMID: 33296008      PMCID: PMC8172412          DOI: 10.1007/s00467-020-04857-0

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


× No keyword cloud information.

Answers

The tumor developed during pregnancy in the upper pole of the left kidney and displayed spindle cell components with no atypia and islands of metaplastic cartilage, which is typical for a congenital mesoblastic nephroma (CMN), classic variant. Wilms tumor (WT)/nephroblastoma is the most frequent kidney tumor in childhood, and this diagnosis has to be considered [1]. Additional immunohistochemical staining is helpful to distinguish CMN from WT with heterologous differentiation [1, 2].

Discussion

Congenital mesoblastic nephroma represents 3% of all pediatric kidney tumors [3]. It is the most common kidney neoplasm diagnosed in the first 3 months of life, and it is frequently detected antenatally, as described in our case [4]. The malignant potential of the tumor is low.

Histopathology

The histological classification of CMN includes three subtypes: classic, cellular, and mixed type [5]. Classic CMN is composed of braiding bundles of spindle cells and frequent metaplastic cartilage with no capsular boundaries. The tumor often infiltrates the surrounding perirenal fat tissue and parenchyma [6]. Cellular CMN also presents bundles of spindle cells but has a stronger hemangiopericytic pattern and a higher mitotic activity than the classic type. In contrast, the cellular type less frequently infiltrates the perirenal fat and/or kidney parenchyma. Mixed CMN shows, as the name indicates, a mixture of both abovementioned types.

Molecular aspects

There are recurrent genetic aberrations described in CMN, including somatic trisomy 11 and, occurring in the cellular and mixed type, the translocation t(12;15)(p13;q25), which results in fusion of ETV6 and NTRK3 [7, 8]. Associations with genetic syndromes are only described in rare cases [8, 9].

Therapy

Complete nephrectomy is curative for most patients with stage I/II disease. The removal of perirenal fat during surgery is important, as CMN tumors often show infiltrative growth into the perirenal fat. However, in case of a high risk of operative or anesthetic complications, preoperative chemotherapy may be considered. Stage III tumors of the classic and mixed histologic subtype are also indicated for nephrectomy alone. Stage III tumors of the cellular type treated only surgically have a higher rate of relapse than the other histologic subtypes requiring chemotherapy or radiotherapy in some cases. However, due to limited data, there are no specific recommendations for adjuvant chemotherapy [8]. The known side effects of radiotherapy particularly in these very young patients limit this treatment modality to selected cases with aggressive tumors not responding to chemotherapy [8]. For the targeted therapy of tumors with the ETV6-NTRK3 fusion, tropomyosin receptor kinase inhibitors have been developed. One drug was recently approved for children with CMN and proven ETV6-NTRK3 fusion who lack other treatment options [10]. However, conclusive data regarding the outcome of patients after application of the drug are not available. Taking into account these aspects, it may be concluded that the decision for the adequate treatment of patients with CMN may sometimes be challenging. Therefore, the importance of an adequate diagnostic and therapeutic plan established by an interdisciplinary reference board which should include a pediatric oncologist, pediatric radiologist, pediatric surgeon, and pathologist cannot be overemphasized.

Conclusion

In summary, CMN is a rare and in most cases a non-aggressive tumor. It is classified into three histological subtypes. Frequently, the tumor is diagnosed antenatally. Most tumors are treated with surgery only. Pre- and postoperative chemotherapy is only administered in particular cases. Nephroblastoma is a possible differential diagnosis.
  7 in total

Review 1.  Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.

Authors:  Noah Federman; Ray McDermott
Journal:  Expert Rev Clin Pharmacol       Date:  2019-09-10       Impact factor: 5.045

2.  Mesoblastic nephroma--a report from the Gesellschaft fur Pädiatrische Onkologie und Hämatologie (GPOH).

Authors:  Rhoikos Furtwaengler; Harald Reinhard; Ivo Leuschner; Jens P Schenk; Ulrich Goebel; Alexander Claviez; Andreas Kulozik; Andreas Zoubek; Dietrich von Schweinitz; Norbert Graf
Journal:  Cancer       Date:  2006-05-15       Impact factor: 6.860

3.  Classical and cellular (atypical) congenital mesoblastic nephroma: a clinicopathologic, ultrastructural, immunohistochemical, and flow cytometric study.

Authors:  G Pettinato; J C Manivel; M R Wick; L P Dehner
Journal:  Hum Pathol       Date:  1989-07       Impact factor: 3.466

Review 4.  Recent advances in pediatric renal neoplasia.

Authors:  Pedram Argani; Marc Ladanyi
Journal:  Adv Anat Pathol       Date:  2003-09       Impact factor: 3.875

5.  ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma.

Authors:  S R Knezevich; M J Garnett; T J Pysher; J B Beckwith; P E Grundy; P H Sorensen
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

6.  Characteristics and survival of 750 children diagnosed with a renal tumor in the first seven months of life: A collaborative study by the SIOP/GPOH/SFOP, NWTSG, and UKCCSG Wilms tumor study groups.

Authors:  Marry M van den Heuvel-Eibrink; Paul Grundy; Norbert Graf; Kathy Pritchard-Jones; Christophe Bergeron; Catherine Patte; Harm van Tinteren; Annie Rey; Carolyn Langford; Jim R Anderson; Jan de Kraker
Journal:  Pediatr Blood Cancer       Date:  2008-06       Impact factor: 3.167

7.  Mesoblastic nephromas: a study of 29 tumours from the SIOP nephroblastoma file.

Authors:  B Sandstedt; J F Delemarre; E J Krul; M F Tournade
Journal:  Histopathology       Date:  1985-07       Impact factor: 5.087

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.